Logo image of IRTC

IRHYTHM TECHNOLOGIES INC (IRTC) Stock Fundamental Analysis

NASDAQ:IRTC - US4500561067 - Common Stock

175.735 USD
+4.66 (+2.72%)
Last: 9/3/2025, 2:30:55 PM
Fundamental Rating

3

Taking everything into account, IRTC scores 3 out of 10 in our fundamental rating. IRTC was compared to 190 industry peers in the Health Care Equipment & Supplies industry. While IRTC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, IRTC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IRTC had negative earnings in the past year.
In the past year IRTC had a positive cash flow from operations.
In the past 5 years IRTC always reported negative net income.
In the past 5 years IRTC reported 4 times negative operating cash flow.
IRTC Yearly Net Income VS EBIT VS OCF VS FCFIRTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of IRTC (-9.59%) is better than 62.11% of its industry peers.
The Return On Equity of IRTC (-89.17%) is worse than 61.58% of its industry peers.
Industry RankSector Rank
ROA -9.59%
ROE -89.17%
ROIC N/A
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
IRTC Yearly ROA, ROE, ROICIRTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

Looking at the Gross Margin, with a value of 69.78%, IRTC is in the better half of the industry, outperforming 78.95% of the companies in the same industry.
In the last couple of years the Gross Margin of IRTC has declined.
The Profit Margin and Operating Margin are not available for IRTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
IRTC Yearly Profit, Operating, Gross MarginsIRTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

5

2. Health

2.1 Basic Checks

IRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IRTC has more shares outstanding
Compared to 5 years ago, IRTC has more shares outstanding
The debt/assets ratio for IRTC is higher compared to a year ago.
IRTC Yearly Shares OutstandingIRTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRTC Yearly Total Debt VS Total AssetsIRTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 3.81 indicates that IRTC is not in any danger for bankruptcy at the moment.
IRTC has a better Altman-Z score (3.81) than 74.74% of its industry peers.
The Debt to FCF ratio of IRTC is 50.31, which is on the high side as it means it would take IRTC, 50.31 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 50.31, IRTC is doing good in the industry, outperforming 66.84% of the companies in the same industry.
A Debt/Equity ratio of 6.25 is on the high side and indicates that IRTC has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 6.25, IRTC is doing worse than 90.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 6.25
Debt/FCF 50.31
Altman-Z 3.81
ROIC/WACCN/A
WACC8.44%
IRTC Yearly LT Debt VS Equity VS FCFIRTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.02 indicates that IRTC has no problem at all paying its short term obligations.
The Current ratio of IRTC (5.02) is better than 75.79% of its industry peers.
A Quick Ratio of 4.88 indicates that IRTC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.88, IRTC belongs to the top of the industry, outperforming 81.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.02
Quick Ratio 4.88
IRTC Yearly Current Assets VS Current LiabilitesIRTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.84% over the past year.
Looking at the last year, IRTC shows a very strong growth in Revenue. The Revenue has grown by 22.37%.
IRTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.49% yearly.
EPS 1Y (TTM)36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.54%
Revenue 1Y (TTM)22.37%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%26.1%

3.2 Future

IRTC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.47% yearly.
The Revenue is expected to grow by 18.04% on average over the next years. This is quite good.
EPS Next Y48.41%
EPS Next 2Y36.59%
EPS Next 3Y34.58%
EPS Next 5Y23.47%
Revenue Next Year24.03%
Revenue Next 2Y20.28%
Revenue Next 3Y18.71%
Revenue Next 5Y18.04%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
IRTC Yearly Revenue VS EstimatesIRTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
IRTC Yearly EPS VS EstimatesIRTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

IRTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IRTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRTC Price Earnings VS Forward Price EarningsIRTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300 -400

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, IRTC is valued a bit cheaper than the industry average as 66.32% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 438.35
EV/EBITDA N/A
IRTC Per share dataIRTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A more expensive valuation may be justified as IRTC's earnings are expected to grow with 34.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.59%
EPS Next 3Y34.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IRTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IRHYTHM TECHNOLOGIES INC

NASDAQ:IRTC (9/3/2025, 2:30:55 PM)

175.735

+4.66 (+2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)10-28 2025-10-28/amc
Inst Owners113.02%
Inst Owner Change-1.78%
Ins Owners1.02%
Ins Owner Change-0.53%
Market Cap5.65B
Analysts86.32
Price Target181.28 (3.16%)
Short Float %8.35%
Short Ratio5.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.39%
Min EPS beat(2)4.68%
Max EPS beat(2)34.09%
EPS beat(4)3
Avg EPS beat(4)6.74%
Min EPS beat(4)-115.67%
Max EPS beat(4)103.85%
EPS beat(8)4
Avg EPS beat(8)-13.84%
EPS beat(12)6
Avg EPS beat(12)-7.25%
EPS beat(16)10
Avg EPS beat(16)-0.64%
Revenue beat(2)2
Avg Revenue beat(2)3.32%
Min Revenue beat(2)1.42%
Max Revenue beat(2)5.22%
Revenue beat(4)3
Avg Revenue beat(4)1.81%
Min Revenue beat(4)-1.42%
Max Revenue beat(4)5.22%
Revenue beat(8)4
Avg Revenue beat(8)0.83%
Revenue beat(12)7
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.8%
PT rev (1m)21.96%
PT rev (3m)31.56%
EPS NQ rev (1m)2.13%
EPS NQ rev (3m)-12.57%
EPS NY rev (1m)10.78%
EPS NY rev (3m)10.78%
Revenue NQ rev (1m)6.62%
Revenue NQ rev (3m)8.45%
Revenue NY rev (1m)4.34%
Revenue NY rev (3m)4.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.59
P/FCF 438.35
P/OCF 89.13
P/B 54.47
P/tB 54.93
EV/EBITDA N/A
EPS(TTM)-2.52
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)0.4
FCFY0.23%
OCF(TTM)1.97
OCFY1.12%
SpS20.46
BVpS3.23
TBVpS3.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.59%
ROE -89.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.78%
FCFM 1.96%
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
F-Score6
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 6.25
Debt/FCF 50.31
Debt/EBITDA N/A
Cap/Depr 243.34%
Cap/Sales 7.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.02
Quick Ratio 4.88
Altman-Z 3.81
F-Score6
WACC8.44%
ROIC/WACCN/A
Cap/Depr(3y)235.33%
Cap/Depr(5y)237.52%
Cap/Sales(3y)7.91%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.54%
EPS Next Y48.41%
EPS Next 2Y36.59%
EPS Next 3Y34.58%
EPS Next 5Y23.47%
Revenue 1Y (TTM)22.37%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%26.1%
Revenue Next Year24.03%
Revenue Next 2Y20.28%
Revenue Next 3Y18.71%
Revenue Next 5Y18.04%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year150.99%
EBIT Next 3Y48.66%
EBIT Next 5Y33.19%
FCF growth 1Y125.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y432.01%
OCF growth 3YN/A
OCF growth 5YN/A